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SARS-coronavirus (SARS-CoV) has recently been identified as the causative agent of SARS. We constructed a series of recombinant DIs
(rDIs), a highly attenuated vaccinia strain, expressing a gene encoding four structural proteins (E, M, N and S) of SARS-CoV individually or
simultaneously. These rDIs elicited SARS-CoV-specific serum IgG antibody and T-cell responses in vaccinated mice following intranasal or
subcutaneous administration. Mice that were subcutaneously vaccinated with rDIs expressing S protein with or without other structural proteins
induced a high level of serum neutralizing IgG antibodies and demonstrated marked protective immunity against SARS-CoV challenge in the
absence of a mucosal IgA response. These results indicate that the potent immune response elicited by subcutaneous injection of rDIs containing S
is able to control mucosal infection by SARS-CoV. Thus, replication-deficient DIs constructs hold promise for the development of a safe and
potent SARS vaccine.
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Severe acute respiratory syndrome (SARS) has become a
priority for healthcare agencies around the world given its
communicability, associated mortality, and the potential for
pandemic spread. As of 31 July 2003, 8,098 SARS cases had
been identified worldwide, resulting in 774 deaths and a
mortality rate of about 9.6% (World Health Organization
statistics). SARS is now known to result from infection with a
novel coronavirus (SARS-CoV) (Drosten et al., 2003; Ksiazek
et al., 2003; Peiris et al., 2003). Evidence that SARS-CoV is the⁎ Corresponding author. Fax: +81 3 5285 1150.
E-mail address: yyokota@nih.go.jp (Y. Tsunetsugu-Yokota).
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doi:10.1016/j.virol.2006.03.020etiologic agent of SARS follows an experimental infection of
macaques (Macaca fascicularis), fulfilling Koch's postulates
(Fouchier et al., 2003). The clinical manifestations of SARS are
hardly distinct from other common respiratory viral infections,
including influenza. Because influenza epidemics might occur
simultaneously with the eventual re-emergence of SARS, an
effective SARS vaccine is urgently required, as well as more
sensitive diagnostic tests specific for SARS.
Structural characterization of SARS-CoV and characteriza-
tion of its complete RNA genome (Marra et al., 2003; Rota et al.,
2003; Ruan et al., 2003) have provided us with the opportunity
to develop a SARS vaccine. Like other coronaviruses, SARS-
CoV is a plus-stranded RNA virus with a 30-kb genome
encoding replicase gene products and the 4 structural proteins;
i.e., spike (S), envelope (E), membrane (M), and nucleocapsid
Fig. 1. Schematic diagram of rDIs constructs expressing SARS-CoV structural
proteins. DNA fragments encoding E, M, N and S proteins were inserted into the
location of the 15.4 kb deletion in DIs using the vaccinia virus transfer vector
pDIsgptmH5. Six rDIs constructs are shown.
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thought to be involved in receptor binding, while the E protein
has a role in viral assembly, the M protein is important for virus
budding, and the N protein has a role in viral RNA packaging
(for review, see reference (Holmes, 2003)). Recently, angioten-
sin-converting enzyme 2 (ACE2) has been identified as a
cellular receptor for SARS-CoV (Li et al., 2003). Thus, the first
step of infection likely involves binding of S protein to the
ACE2 receptor. In a model of MHV infection, S protein is
known to contain important virus-neutralizing epitopes that
elicit neutralizing antibody responses in mice (Collins et al.,
1982). Therefore, the S protein of coronavirus might be
manipulated to induce immunity. However, S, M, and N
proteins are also known to contribute to the host immune
response (Anton et al., 1996; Jackwood and Hilt, 1995). A DNA
vaccine encoding the S glycoprotein of the SARS-CoV induces
T cell and neutralizing antibody responses, as well as protective
immunity, in a mouse model (Yang et al., 2004). Vaccination
with a plasmid expressing N protein is capable of generating
strong N-specific humoral and T-cell-mediated immune
responses in vaccinated C57BL/6 mice (Kim et al., 2004;
Zhao et al., 2005; Zhu et al., 2004). In addition, N-specific
CD8+ T cells provide protective immunity against some
coronaviruses (Collisson et al., 2000; Seo et al., 1997).
The DIs strain is a highly restricted host range mutant of the
vaccinia virus isolated by successive 1-day egg passage of the
DIE vaccinia strain, an authorized strain for smallpox vaccine
and actually used in Japan until 1981. DIs does not replicate and
is not pathogenic in mice, guinea pigs or rabbits. Furthermore,
the DIs does not replicate in various mammalian cell lines
(Tagaya et al., 1961). Recently, we established a system for
foreign gene expression by inserting target genes into this
strain, after which expression of (i) bacteriophage T7
polymerase, and (ii) the full-length HIV-1NL432 gag gene, was
observed (Ishii et al., 2002), thus demonstrating the usefulness
of this system.
In the present study, we constructed a recombinant vaccinia
virus DIs expressing one or more SARS-CoV structural
proteins (E, M, N, and S, or a combination of E, M, and S
(E/M/S), or E, M, N and S (E/M/N/S)). These rDIs vaccines
were administered to mice either subcutaneously or intranasal-
ly, and the humoral and cellular immunity against SARS-CoV
in vaccinated mice were analyzed. We demonstrated here that
replication-deficient DIs constructs expressing S protein alone
or in combination with other components, but not N alone,
elicited strong protective immune responses against SARS-
CoV infection.
Results
Expression of SARS-CoV structural proteins by rDIs
The structures of transfer vectors used in this study
(pDIsSARS-E, pDIsSARS-M, pDIsSARS-N, pDIsSARS-S,
pDIsSARS-E/M, pDIsSARS-E/M/S and pDIsSARS-E/M/N/
S) were summarized in Fig. 1. Expression of SARS-CoV N
and S proteins in chick embryo fibroblast (CEF) cells infectedwith rDIsSARS was detected by Western blotting using
monoclonal antibodies (Fig. 2A) (Ohnishi et al., 2005).
Purified SARS-CoV virion was used as a positive control
(Fig. 2A, lane PC). A robust signal was detected at 50 kDa,
corresponding to the N protein of SARS-CoV, as predicted by
its genomic size (Marra et al., 2003; Rota et al., 2003). A band
approaching 200 kDa likely corresponds to the S protein,
which is known to be heavily glycosylated (Fig. 2A). Our
results are consistent with data reported by Xiao et al. (2003)
who expressed the full-length S glycoprotein of SARS-CoV
Tor2 strain in 293 cells and demonstrated a protein approach-
ing 180–200 kDa by SDS gel electrophoresis. Concerning the
M protein, only a smear band in the stacking gel was detected
using a polyclonal antibody against synthetic peptide of the M
protein (Mizutani et al., 2004), presumably because it formed
large oligomers with SDS-resistance in cells (Fig. 2A). Similar
result was mentioned by the analysis of the M protein of
SARS-CoV (Buchholz et al., 2004) and infectious bronchitis
virus (Weisz et al., 1993).
The subcellular localization of S, M, and N proteins was
analyzed by immunofluorescence staining. Cells infected with
rDIsSARS-M demonstrated M proteins primarily co-localized
with the Golgi marker GM-130 (Fig. 2B), which is consistent
with the results of the recent study (Nal et al., 2005).
Individually expressed SARS-CoV N protein could be
detected partially with Golgi apparatus, but remained princi-
pally localized to the cytoplasm (Fig. 2B). Overexpressed
recombinant SARS-S glycoprotein could be detected partially
with Golgi apparatus, but also be detected throughout the
cytoplasm (Fig. 2B). These results indicate that cells infected
with rDIsSARS expressed significant levels of SARS-CoV
proteins under the control of mH5 promoter with an expected
post-translational processing (Nal et al., 2005; You et al.,
2005).
Fig. 2. Western blot analysis and indirect immunofluorescence analysis. (A) CEF cells were infected with rDIs constructs expressing SARS-CoV structural
proteins (M, N and S, respectively). Purified SARS-CoV virion (0.5 μg) was used as a positive control. SARS-CoV proteins were detected using monoclonal
antibodies (N and S) or polyclonal antibodies (M). Detection of bound antibodies was done with horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit
antibody, and visualized by chemiluminescence. (B) CEF cells were infected with rDIs constructs expressing SARS-CoV structural proteins (M, N and S,
respectively). To detect SARS-CoV proteins, the cells were incubated with rabbit polyclonal antibodies against these proteins. The cells were further incubated
with FITC-conjugated goat anti-rabbit IgG. To analyze subcellular localization of these proteins, monoclonal antibody against GM-130 (Golgi marker) and
rhodamine-conjugated goat anti-mouse IgG were used. SARS proteins are shown in green, Golgi apparatus is shown in red and co-localization, where it occurs,
is shown in yellow.
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SARS-CoV
To examine the anti-SARS-CoV response in mice after
inoculation with rDIsSARS, four mice in each group were
subcutaneously or intranasally inoculated three times with
10 pfu of rDIsSARS-N, rDIsSARS-M, rDIsSARS-S, rDIs-
SARS-E/M/S or rDIsSARS-E/M/N/S. Ten days after the
final inoculation, vaccinated mice were observed to have
high levels of anti-SARS-CoV IgG antibodies in their sera
(Fig. 3).
In order to prove effective vaccination, we next examined
whether neutralizing antibodies against SARS-CoV were
elicited in these mice. Neutralizing antibodies againstSARS-CoV were induced in mice following subcutaneous
or intranasal injection of rDIsSARS-S, rDIsSARS-E/M/S, or
rDIsSARS-E/M/N/S, but not in mice immunized with
rDIsSARS-N or rDIsSARS-M. These results of ELISA data
were incorporated into Fig. 3 by depicting the neutralization
positive serum as closed circles. Thus, our results, consistent
with others (Bisht et al., 2004; Buchholz et al., 2004; Yang
et al., 2004), indicate that the S protein is a prerequisite for
eliciting a sufficient IgG antibody response for neutralization.
Similar neutralizing activity was obtained in mice receiving S
alone or in combination with other components. Therefore,
we expected that the rDIsSARS expressing E/M/N/S proteins
in combination could be the best vaccine candidate among
others.
Fig. 3. Detection of anti-SARS-CoV IgG in vaccinated mice. IgG antibody
levels against SARS-CoV were determined as described in Materials and
methods. SARS-CoV-specific IgG titers were calculated as follows: SARS-
specific IgG titer (ELISA units/ml) = (the unit value obtained for wells coated
with virus-infected cell lysate) − (the unit value obtained for wells coated with
non-infected cell lysate). *P < 0.1, **P < 0.05, ***P < 0.01 vs. DIs-
administered group. The data for neutralizing sera are represented by closed
circles and the data for non-neutralizing sera are represented by open circles.
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induces SARS-CoV-specific IgA in nasal mucosa and a high
level of mucosal IgG in parallel with that of serum IgG
Mucosal IgA response is believed to be crucial for the
protective immunity against various pathogens (Meeusen et al.,
2004). We, next, examined mucosal immunity in the respiratory
tracts of mice inoculated with rDIsSARS either subcutaneously
or intranasally. The level of anti-SARS-CoV IgA within nasal
wash fluid of vaccinated mice was determined by enzyme-
linked immunosorbent assay (ELISA). As shown in Fig. 4A,
substantial levels of anti-SARS-CoV IgAwere detected only in
mice received intranasal inoculation of rDIsSARS-E/M/N/S,
compared to those inoculated with parental DIs (P = 0.0010).
The level of IgA detected in intranasally rDIsSARS-E/M/N/S-
inoculated mice was similar to that observed following
intranasal immunization with UV-inactivated, purified SARS-
CoV virion (positive control). On the other hand, subcutaneous
injection of all forms of rDIsSARS produced only slightly
higher levels of IgA than those observed in DIs -injected control
mice. Therefore, the results indicated that the subcutaneous
route of injection is inefficient, especially when mucosal IgA
response is required.
Since neutralizing activity was, nevertheless, detected in the
nasal washes of mice following subcutaneous immunization
(data not shown), we also measured anti-SARS-CoV IgG levels
in the nasal washes of these mice (Fig. 4B). High levels of IgG
were detected in the nasal washes of mice following nasal
immunization, which were observed to correspond well with
IgG levels in the serum (Fig. 4C). A similar trend was observed
in mice following subcutaneous immunization, despite at alower level than in mice immunized intranasally. These results
suggest that neutralizing IgG antibodies are capable of reaching
the mucosal surface if plasma levels are high enough.
Protection of rDIsSARS-immunized mice from nasal SARS-CoV
challenge is achieved without mucosal IgA response
The level of protection against SARS-CoV challenge in mice
following inoculation with rDIsSARS is a critical issue for the
vaccine development. We inoculated three times with 10 pfu of
rDIsSARS-N, rDIsSARS-E/M/S or rDIsSARS-E/M/N/S into
four mice in each group either subcutaneously or intranasally.
One week after final inoculation, the mice were challenged
intranasally with 104 tissue culture 50% infectious dose
(TCID50) of SARS-CoV. The results were shown in Fig. 4D.
In mice inoculated with saline, 103 TCID50/ml of SARS-CoV
were recovered from lung wash fluid on day 3. In contrast, titers
of SARS-CoV from the lungs of mice subcutaneously
immunized with rDIsSARS-E/M/S or rDIsSARS-E/M/N/S
were below the limits of detection. The same was true for
mice intranasally immunized with rDIsSARS-E/M/N/S, where-
as the virus was recovered in mice similarly immunized with
rDIsSARS-E/M/S. Taken into consideration of a relatively low
or marginal level of mucosal IgA antibody in mice intranasally
immunized with rDIsSARS-E/M/N/S or rDIsSARS-E/M/S, or
even no IgA response by subcutaneous route as described
above, it was suggested that mucosal IgG antibody, but not IgA
antibody, likely contributed to the protective immunity,
especially in mice simultaneously immunized with recombinant
rDIsSARS-E/M/N/S.
On the other hand, titers of SARS-CoV from the lung wash
fluid of mice intranasally or subcutaneously immunized with
rDIsSARS-N, were similar or slightly lower than the titers of
negative controls, suggesting that intranasal or subcutaneous
administration of rDIsSARS-N does not protect mice from
SARS-CoV challenge, which is highly reflected by the non-
neutralizing nature of anti-SARS-CoV N antibodies.
Cellular immunity induced by rDIsSARS
Although now we know that the systemic neutralizing IgG
antibody against SARS-CoV S protein is a major component of
protective immunity, T cell responses are also important to
protect hosts from various viral infection. In a previous study of
coronaviruses, S protein was shown to play an important role in
viral pathogenesis, as well as induction of protective immunity
(Holmes, 2003). In order to assess the ability of rDIsSARS to
induce SARS-CoV S-specific T cells, T cells from axillary
lymph nodes (ALN), superficial cervical lymph nodes (CLN)
and spleens of mice subcutaneously immunized with rDIs-
SARS-S or DIs were isolated and stimulated in vitro with UV-
inactivated, purified SARS-CoV virion. Culture supernatant
was collected 4 days later, and the levels of interferon-γ (IFN-
γ), interleukin (IL)-2, IL-4, IL-5 and tumor necrosis factor-α
(TNF-α) were measured. T cells in ALN produced the greatest
cytokine levels (Fig. 5, and data not shown). This is not
surprising in light of the subcutaneous route of immunization.
Fig. 4. Mucosally secreted anti-SARS-CoV IgG, but not IgA, antibodies are protective from nasal SARS-CoV challenge in vaccinated mice. The levels of Ig A and IgG
antibodies against SARS-CoV were determined as described in Materials and methods. (A) Titers of anti-SARS-CoV IgA in the nasal washings of vaccinated mice.
Error bars represent the mean ± SD. (B) Titers of anti-SARS-CoV IgG in the nasal washings of vaccinated mice. Error bars represent the mean ± SD. (C) Titers of anti-
SARS-CoV IgG in the sera of vaccinated mice. Error bars represent the mean ± SD. (D) The titers of SARS-CoV in the lungs of vaccinated mice challenged 1 week
later with 104 TCID50 of SARS-CoV. Virus titers are expressed as log10TCID50. Error bars represent the mean ± SD. *P < 0.1, **P < 0.05, ***P < 0.01 vs. DIs-
administered group.
372 K. Ishii et al. / Virology 351 (2006) 368–380Notably, mice immunized with rDIsSARS-S produced a high
level of IFN-γ upon in vitro stimulation with UV-inactivated,
purified SARS-CoV virion. The production of TNF-α, an
inflammatory cytokine, was significantly elevated in T cells inFig. 5. In vitro response of SARS-CoV-specific T cells in mice subcutaneously immun
after the third vaccination of either DIs control or rDIsSARS-S. After preparation of s
cell depleted normal BALB/c mouse splenocytes as APCs in the presence or absence
and TNF-α concentrations in the culture supernatant were measured.ALN of rDIsSARS-S immunized mice after in vitro stimulation
with virion antigens. However, TNF-α production was
observed also in mice immunized with parental DIs without
in vitro stimulation with virion antigens. Since T cells from theized with rDIsSARS-S. CLN, ALN and spleens were obtained frommice 1 week
ingle cell suspensions, T cells were purified and cultivated with irradiated and T-
of 10 μg/ml of purified UV-irradiated SARS-CoV virion. Four days later, IFN-γ
373K. Ishii et al. / Virology 351 (2006) 368–380lymph nodes of naïve mice did not produce cytokines even after
in vitro stimulation with virion antigens (data not shown), it is
possible that injection of DIs induces mild local inflammation,
even when viral proliferation does not occur at the injection site.
The pattern of IL-2, IL-5 and IL-4 production were similar to
that of IFN-γ, and the maximum level of these cytokines in
ALN T cells from rDIsSARS-S-immunized mice were 254, 227
and 88 ng/ml, respectively.
Next, we analyzed the antigenic epitopes of SARS-CoV-
specific T cells in the spleen. We carried out IFN-γ enzyme-
linked immunospot (ELISPOT) analysis using four 20-mer
peptides corresponding to the ACE2 binding region of the S
protein selected using the SYFPEITHI score (S44-47), as well
as overlapping 20-mer peptides pool covering a whole N
protein. When the splenic T cells of mice were analyzed
following intranasal or subcutaneous immunization with the
most potent vaccine, rDIsSARS-E/M/N/S, a high level of
reactivity against S46 was observed especially in the T cells of
subcutaneously immunized mice (Fig. 6A). Zhi et al. recently
identified a CD4+ T cell epitope, known as NYNYKYRYL, in
BALB/c mice (Zhi et al., 2005). S46 contains this sequence,
thus, these IFN-γ-producing T cells are likely CD4+ T cells. To
detect N-specific T cells, mice subcutaneously or intranasally
immunized with rDIsSARS-N were analyzed by ELISPOT. In
this case, ten peptides were pooled from amino-terminus of N
protein, resulting in 5 pools of peptides. We thus detected N-
reactive T cells capable of recognizing the first 10 peptides pool
(Fig. 6B), and observed a greater proportion of N-specific T
cells following nasal immunization than subcutaneous immu-
nization. These results indicate that S- and N-specific T cells are
generated systemically by rDIs.
In order to elucidate whether or not SARS-CoV-specific
CD8+ T cells were induced by immunization with the rDIs, the
splenic T cells of mice subcutaneously or intranasally
immunized with rDIsSARS-E/M/N/S were further analyzed
by ELISPOT using a stably S-expressing A20.2J B cell S6.2Fig. 6. Detection of SARS-CoV-specific T cells elicited by rDIsSARS-E/M/N/S or rD
immunized with recombinant rDIsSARS-E/M/N/S (A) or rDIsSARS-N (B) were sepa
performed. (A) T cells (5 × 105 cells) from mice immunized with rDIsSARS-E/M/N/S
membrane plates coated with IFN-γ capture antibody in the absence or presence of 5 μ
counted and are depicted. (B) T cells from mice immunized with rDIsSARS-N and A
divided into 5 parts by 100 amino acids (A, B, C, D and E) and 10 peptides each of po
used as an antigen.clone, as an antigen presenting cells (APC). Expression of S
protein on the S6.2 clone was confirmed by FACS analysis
using anti-SARS S monoclonal antibody (Fig. 7A). An empty
vector transfectant, BOS-5, was used as a negative control APC.
Subcutaneous and intranasal immunization with the most potent
rDIsSARS-E/M/N/S generated a significant level of S-specific
T cells (Fig. 7B), and a dramatic decrease in S-specific T cells
was observed following partial depletion of CD8+ T cells (Fig.
7C). Therefore, rDIsSARS-E/M/N/S was able to induce both
SARS-CoV-reactive CD4+ and CD8+ T cells.
Histopathological findings
The immunogenicity of rDIs expressing SARS-CoV struc-
tural proteins was further evaluated by histopathological and
immunohistochemical analysis of lung tissue in mice, the
primary infection site of SARS-CoV (Fig. 8). Slight migration
of inflammatory cells and mild disruption of the bronchial
epithelium were detected in lung tissue of mock-vaccinated
mice. SARS-CoV antigens were diffusely observed within the
bronchial and alveolar epithelium. In contrast, significant
lymphocytic infiltration into peribronchial sites, with little to
no detection of SARS-CoV antigens, was observed in mice
intranasally immunized with rDIsSARS-E/M/S or rDIsSARS-
E/M/N/S (Fig. 8). The infiltrating lymphocytes were found to be
CD3-positive T-cells, as determined by immunohistochemistry
with anti-CD3 antibody (Fig. 8). On the other hand, intranasal
or subcutaneous immunization by only N-expressing DIs
induced neither T-cell infiltration nor protective immunity
against SARS-CoV, despite of the induction of N-specific
antibodies and T cells. These results suggest that marked
induction of T-cell response in mice immunized with rDIs-
SARS-E/M/S and rDIsSARS-E/M/N/S help to eliminate SARS-
CoV from the lung tissue. On the other hand, intranasal or
subcutaneous immunization by only N-expressing DIs did not
induce protective immunity against SARS-CoV, despite of theIsSARS-N vaccination. Splenic and lymph node (LN) T cells of mice s.c. or i.n.
rated using a MACS system (Miltenyi Biotec), and IFN-γ ELISPOTanalysis was
were cultured with irradiated A20.2J B cells (1 × 104), in triplicate, in a 96-well
M of S peptides (S44–S47). The numbers of IFN-γ spot-forming cells were then
20.2J B cells were cultured as described in A. N protein (422 amino acids) was
oled 20-mer overlapping peptides specific to the each stretch of N sequence were
Fig. 7. Detection of SARS-CoV S-specific CD8+ T cells in mice immunized with rDIsSARS-E/M/N/S. (A) A20.2J B cell clone expressing S (S6.2) or empty vector
(BOS-5) was stained with biotinylated anti-SARS-CoV S monoclonal antibody (solid line) or control IgG (shadowed line), followed by the incubation with
streptavidin-APC, and then analyzed by FACScalibur. A histogram of APC fluorescence of gated live cells (PI negative) is depicted. (B) Splenic T cells from mice
immunized s.c. or i.n. with recombinant rDIsSARS-E/M/N/S were purified and IFN-γ ELISPOTanalysis was carried out using γ-irradiated S6.2 and BOS-5 as APCs.
The number of T cells reactive for BOS-5 control (white column) and S6.2 (black column) cells are shown. Error bars represent the mean ± SD. (C) Using the same
splenic T cells as in panel B, CD8+ T cells were partially removed using anti-CD8 mAb-coated magnetic beads (Miltenyi Biotec), and the number of T cells reactive for
BOS-5 and S6.2 cells were counted by ELISPOT. The number of BOS-5-reactive T cells was subtracted and the number of S-specific T cells is depicted. Black
columns: total T cells; grey columns: partially CD8-depleted T cells.
374 K. Ishii et al. / Virology 351 (2006) 368–380induction of N-specific antibodies and T cells. Thus, rDIs
expressing the S protein, along with other membrane compo-
nents (E/M and E/M/N), are capable of inducing strong
immunity of both humoral and cellular arms and are fully
competent to clear SARS-CoV infection.
Discussion
The DIs strain, which replicates well in CEF cells but not in
most mammalian cells, was isolated from the DIE strain of the
vaccinia virus during serial 1-day egg passage, and it is
characterized by the induction of tiny pocks on chicken
chorioallantoic membrane (Tagaya et al., 1961; Kitamura et
al., 1967; Ishii et al., 2002). The DIs-derived recombinant
viruses express high levels of viral and inserted genes, even in
non-permissive cell lines without any cytopathic effects (Ishii et
al., 2002). In earlier studies, MVA strain of vaccinia virus,
which is also replication-incompetent in most mammal cells,
was used to express a variety of foreign genes and some of these
recombinant viruses were studied as candidate vaccine vectors
and appeared to be more effective than many replication-
competent vaccinia virus vaccines (Sutter and Moss, 1992;Sutter et al., 1994; Belyakov et al., 1998; Nam et al., 1999;
Stittelaar et al., 2000). rDIs does not replicate nor produce
infectious virions in most mammalian cells, therefore the DIs
strain has a safety advantage when used as a recombinant
vaccine vector as for MVA. Recently, a recombinant DIs,
rDIsSIVGag, expressing a full-length gag gene of SIV, was
developed, and demonstrated to have a potential for use as an
HIV/AIDS vaccine (Someya et al., 2004).
Attempts at vaccine development against SARS-CoV are
ongoing by a number of organizations using various techniques
(see review, (Groneberg et al., 2005)). DNA vaccines (Kim et
al., 2004; Yang et al., 2004; Zhu et al., 2004; Zhao et al., 2005)
and viral vectors such as vaccinia virus (Bisht et al., 2004;
Weingartl et al., 2004), parainfluenza virus (Bukreyev et al.,
2004), adenovirus (Zakhartchouk et al., 2005) and rhabdo-
viruses (Faber et al., 2005; Kapadia et al., 2005) are used as
recombinant vaccines. Yang et al. (2004) showed that viral
replication was reduced by more than six orders of magnitude in
the lungs of mice vaccinated with these S plasmid DNA
expression vectors, and protection was mediated by a humoral
but not a T-cell-dependent immune mechanism. Bisht et al.
(2004) showed that inoculation of BALB/c mice with a
Fig. 8. Histopathology and immunohistochemistry. Lung specimen of mice immunized with rDIs expressing structural proteins of SARS-CoV and challenged with
SARS-CoV. Mice were immunized i.n. or s.c. with DIs, rDIsSARS-N, rDIsSARS-E/M/S, rDIsSARS-E/M/N/S or saline. Mice were challenged with SARS-CoV 2
weeks after the final vaccination. Lungs were harvested 3 days after the challenge. The section was stained with hematoxylin and eosin (H&E) or
immunohistochmically stained with anti-SARS-CoV antibody or anti-CD3 antibody.
375K. Ishii et al. / Virology 351 (2006) 368–380recombinant MVA expressing SARS-CoV S protein elicited
serum antibodies to SARS-CoV S protein and protective
immunity against SARS-CoV infection. Previous studies
demonstrated passive transfer of serum from immunized mice
conferred protection against SARS-CoV in the respiratory tract
following inoculation with either SARS CoV or recombinant
MVA expressing S protein (Bisht et al., 2004; Subbarao et al.,
2004). These results suggest that S protein is a crucial antigen in
generating protective immunity. We observed that intranasal or
subcutaneous inoculation of BALB/c mice with rDIs expressing
S protein (rDIsSARS-S, rDIsSARS-E/M/S or rDIsSARS-E/M/
N/S) produced serum antibodies capable of recognizing theSARS-CoV virion by ELISA, also capable of neutralizing
SARS-CoV in vitro. The subcutaneous route appears to elicit
stronger immunity than intranasal immunization with respect to
the level of anti-SARS-CoV IgG antibody produced. Important
finding here is that although the mucosal IgA antibody response
was induced only in mice intranasally immunized with
rDIsSARS-E/M/N/S, the mice administered with rDIsSARS-
E/M/N/S by either route elicited strong protective immunity.
Therefore, the protection was achieved in the absence of a
mucosal IgA response in mice subcutaneously immunized with
rDIsSARS-E/M/N/S. Thus, our results clearly show that
mucosal infection might be prevented in the presence of a
376 K. Ishii et al. / Virology 351 (2006) 368–380high level of neutralizing serum IgG antibody. Control mice
vaccinated with DIs not expressing envelope proteins were not
protected, indicating that the effect was specific for the
expressed envelope proteins of SARS-CoV and was not due
to enhanced nonspecific immunity.
A recent report suggests that a combination of three
adenovirus vector expressing SARS-S, -M and –N protein is
capable of eliciting neutralizing antibodies in serum and N-
specific T cell responses in rhesus macaques (Gao et al., 2003).
However, in this report, the relationship between these
immune responses and actual protection was not presented.
In another study, the importance of SARS-CoV structural
proteins in generating protective immunity was investigated by
expressing them individually and in combination using a
recombinant parainfluenza virus (PIV) type 3 vector. The
expression of S with the two other putative virion envelope
proteins, M and E protein, did not augment the neutralizing
antibody response. In the absence of S, expression of M and E,
or the nucleocapsid protein N, did not induce a detectable
serum SARS-CoV-neutralizing antibody response (Buchholz
et al., 2004). Our results were consistent with this in that
expression of M or N proteins by administration of DIs
harboring SARS-CoV M or N gene singly did not induce a
neutralizing antibody response, although anti-SARS-CoV
antibodies were detected by ELISA.
Recent studies have shown that vaccination with a plasmid
expressing N protein can elicit SARS-CoV nucleocapsid-
specific humoral and cellular immune responses (Kim et al.,
2004; Zhu et al., 2004; Zhao et al., 2005). They showed that
linkage of N protein to calreticulin, Ca2+-binding protein known
to enhance immune response, in a DNA vaccine resulted in the
significant enhancement of the humoral and cellular immune
responses to N protein in vaccinated mice. They also showed
that the N protein-specific DNA vaccine elicited partial
protection against N protein expressing vaccinia virus chal-
lenge, however, the efficacy of N-specific cellular immune
responses in protection of SARS-CoV infection is not clear.
Although we here showed that N protein expression by rDIs
was capable of eliciting N-specific humoral and cellular
immunity, vaccination with rDIsSARS-N failed to elicit a
neutralizing antibody response against SARS-CoV infection in
vitro, and failed to confer full protection in vaccinated mice
against SARS-CoV challenge, suggesting that SARS-CoV N
protein-specific antibodies and CTLs were not sufficient to
provide full protection against SARS-CoV infection.
Histopathological analysis of lung tissues in the present
study revealed a marked lymphocytic infiltration in peribron-
chial sites in mice immunized intranasally or subcutaneously
with recombinant vaccinia virus DIs expressing E/M/S or E/
M/N/S. Almost no SARS-CoV antigens were detected in these
areas upon immunohistochemical analysis. The infiltrating
lymphocytes were shown to be CD3 positive T-cells. This is
the first evidence of induction of protective immunity against
SARS-CoV associated with marked infiltration of T cells at a
SARS-CoV infection site. We were able to detect SARS-CoV
S-specific CD8+ T cells in the spleen of these immunized
mice by INF-γ ELISPOT. Thus, these results suggest that Tcell induction in mice immunized with rDIsSARS-E/M/S and
rDIsSARS-E/M/N/S might provide additional help to com-
pletely eliminate SARS-CoV in the lung. Of note, Weingartl
et al. (2004) reported a low level of neutralizing antibody
response in ferrets (Mustela putorius furo) immunized with a
recombinant MVA expressing SARS-CoV S protein. They
also showed that there are more rapid and vigorous
neutralizing antibody responses in immunized ferrets, com-
pared to control animals after challenge with SARS-CoV.
However, SARS-CoV infection and spreading in the immu-
nized ferrets is not prevented. Moreover, upon infection with
SARS-CoV, strong inflammatory responses were noted in
ferrets immunized with either recombinant MVA expressing
SARS-CoV S or N protein, suggesting that vaccination with
the recombinant MVA expressing SARS-CoV S or N protein
may, in some case, lead to enhanced pathology during SARS-
CoV infection (Czub et al., 2005; Weingartl et al., 2004). It
was also reported that antibodies that neutralized most human
SARS-CoV S enhanced entry mediated by the civet virus S,
suggesting the possibility that such kind of vaccines might
enhance viral infection (Yang et al., 2005). Although we
observed no such pathology in rDIs-immunized mice after
virus challenge, the potential for widespread tissue damage
following administration of SARS-CoV proteins should be
carefully investigated. In addition, further studies are required
to clarify whether the recruited T-cells indeed play an
important role in clearance of SARS-CoV from sites of
infection.
In this study, we constructed rDIs containing genes
encoding four structural proteins of SARS-CoV that were
individually or simultaneously expressed. Intranasal or subcu-
taneous inoculation of BALB/c 3T3 mice with rDIs expressing
S protein with or without other structural proteins elicited a
high level of neutralizing antibodies against SARS-CoV and
protective immunity, in the lungs of mice after intranasal
challenge. Furthermore, both cellular and mucosal immunity
against SARS-CoV structural proteins were also induced
following administration of the rDIs. Therefore, the replica-
tion-deficient DIs strain is a feasible, safe and effective SARS
vaccine vector.
Materials and methods
Cells
CEF cells and Vero E6 cells were grown in Dulbecco's
modified essential medium (DMEM) supplemented with 10%
fetal bovine serum (FCS), 1% penicillin-streptomycin and L-
glutamine (GIBCO BRL/Life Technologies, Gaithersburg,
MD). A20.2J murine B cells were maintained in RPMI1640
supplemented with 10% FCS, 50 μM β-mercaptoethanol, L-
glutamine and antibiotics.
Plasmid DNA constructs and DNA preparation
cDNA encoding SARS-CoV structural proteins were
generated by reverse transcription of SARS-CoV HKU39849
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Corp., Carlsbad, CA), followed by amplification using expand
high fidelity PCR system (Roche diagnostics), as described
previously (Ohnishi et al., 2005). These DNA fragments
encoding E, M, N and S proteins were cloned into the vaccinia
virus transfer vector pDIsgptmH5, which also harbored E. coli
xanthine-guanine phosphoribosyltransferase, under control of a
vaccinia virus p7.5 promoter in the cloning site of pUc/DIs
(Ishii et al., 2002), to generate pDIsSARS-E, pDIsSARS-M,
pDIsSARS-N, and pDIsSARS-S, respectively. To construct
transfer vectors to generate rDIs expressing E/M, E/M/S, or E/
M/N/S, DNA fragments encoding M, N and S proteins
controlled by the mH5 promoter of the vaccinia virus (Wyatt
et al., 1996) were inserted into pDIsSARS-E SmaI, NotI and
SacI sites, respectively, thus generating pDIsSARS-E/M,
pDIsSARS-E/M/S and pDIsSARS-E/M/N/S (Fig. 1). A plasmid
expressing S driven by the EF-1α promoter was constructed
using pEF-BOS-bst (Yoshizawa et al., 2001), and designated
pEF-S-bst.
Generation of recombinant vaccinia virus
Recombinant forms of DIs were obtained by hypoxanthine-
guanine phosphoribosyltransferase selection (Falkner and
Moss, 1988). Monolayers of CEF cells in 6-well plates were
pre-incubated with DMEM containing 10% FCS, 25 μg/ml of
micophenoic acid (MPA), 250 μg/ml of xanthine and 15 μg/ml
of hypoxanthine. Infection was performed onto CEF cells
grown in 8 cm dishes with DIs at a multiplicity of infection
(moi) of 1.0. Transfection was performed using 20 μg of each
DIs transfer vector and Lipofectamine (GIBCO BRL/Life
Technologies). rDIs expressing SARS-CoV structural proteins
were selected following four consecutive rounds of plaque
purification of CEF cells in 6-well plates pre-incubated with
DMEM containing 10% FCS, 25 μg/ml of MPA, 250 μg/ml of
xanthine, and 15 μg/ml of hypoxanthine. Resultant rDIs
expressing SARS-CoV structural proteins were designated as
rDIsSARS-E, rDIsSARS-M, rDIsSARS-N, rDIsSARS-S, rDIs-
SARS-E/M, rDIsSARS-E/M/S and rDIsSARS-E/M/N/S, re-
spectively, and subsequently maintained in CEF cells for use in
further studies.
Western blot analysis
CEF cells infected with rDIs constructs harboring ORFs of
SARS-CoV structural proteins were fractionated by SDS-PAGE
under reduced conditions. Purified SARS-CoV virion (0.5 μg)
was used as a positive control. The proteins were then
transferred to an Immobilon-P PVDF membrane (MILLIPORE,
Bedford, MA) and incubated with monoclonal antibodies
against N or S proteins (Ohnishi et al., 2005) or polyclonal
antibody against M protein (Mizutani et al., 2004). After
washing, the membrane was reacted with HRP-conjugated Fab
fragment of anti-mouse or rabbit IgG (H + L) (1:20,000, Santa
Cruz Biotechnology, Santa Cruz, CA), followed by visualiza-
tion of the bands using chemiluminescent reagents (Pierce,
Rockford, IL).Indirect immunofluorescence analysis
CEF cells were infected with rDIs expressing SARS-CoV
structural proteins. After 48 h of incubation, the cells were
washed with PBS and fixed with 3% paraformaldehyde in PBS
for 20 min at room temperature. The fixed cells were then
permeabilized with 0.2% Triton X-100 for 3 min at room
temperature, and then blocked with a non-fat milk solution,
Block Ace (Yukijirushi Co., Tokyo, Japan). The cells were
incubated with polyclonal antibodies against M, N or S proteins
(Mizutani et al., 2004) for 60 min at 37 °C. The cells were
further incubated with fluorescein isothiocyanate (FITC)-
conjugated goat anti-rabbit IgG (TAGO, Burlingame, CA)
diluted to 1:500 in PBS to detect SARS-CoV M, N or S
proteins. To analyze the subcellular localization of SARS
structural proteins, anti-GM-130 monoclonal antibody (BD
Biosciences, Mississauga, ON, Canada) and rhodamine-conju-
gated goat anti-mouse IgG (TAGO) were used to stain the Golgi
apparatus.
Vaccination
Animal studies were carried out under a protocol approved
by the Animal Care and Use Committee of the National Institute
of Infectious Diseases, Japan. Five- to 6-week-old female
BALB/c mice were purchased from Japan SLC (Hamamatsu,
Japan) and immunized with 106 pfu of rDIs, either subcutane-
ously (s.c.) or intranasally (i.n.). After 2 and 6 weeks, identical
titers of recombinant virus were re-administered. One week
later, the mice were intranasally challenged with 104 TCID50 of
SARS-CoV in 20 μl of saline as previously described (Subbarao
et al., 2004). Three days later, serum, nasal wash fluid and
bronchoalveolar wash fluid were collected to measure viral
titers and antibodies against SARS-CoV from mice that were
sacrificed under anesthesia with chloroform.
Detection of SARS-CoV specific IgA and IgG antibodies
IgA and IgG titers against SARS-CoV were determined by
ELISA, as previously described (Takasuka et al., 2004). Briefly,
microtiter plates (Dynatech, Chantily, VA) were coated
overnight at 4 °C with SARS-CoV-infected or mock-infected
Vero E6 cell lysate samples previously treated with 1% NP40,
followed by UV-inactivation. The plates were blocked with 1%
OVA in PBS–0.05% Tween 20, and then incubated with serially
diluted sera (1:10–1:255) for 1 h at room temperature. The
plates were then incubated with either peroxidase-conjugated
anti-mouse IgG (1:2000, Zymed, South San Francisco, CA) or
IgA (1:2000, Southern Biotechnology, Birmingham, AL)
antibody. The plates were washed three times with PBS-
Tween at each step. The substrate mixture (o-phenylenediamine
(Zymed) and hydrogen peroxide) was added to each well, and
the absorbance of each well was read at 490 nm using a model
680 microplate reader (Bio-Rad, Hercules, CA). To provide a
standard for IgG detection, serum was obtained from a hyper-
immunized mouse and the OD490nm value of 100 ELISA
units/ml of standard serum was around three in every assay.
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ing the optical density of wells coated with non-infected cell
lysate from the optical density of wells coated with virus-
infected cell lysate. As a positive control to induce SARS-CoV-
specific IgA, mice were immunized intranasally with UV-
inactivated purified SARS-CoV together with 3 μg of poly(I:C)
(Ichinohe et al., 2005).
SARS-CoV neutralizing assay
Sera collected from vaccinated mice were inactivated by
incubation at 56 °C for 30 min. The serially diluted mice sera
(up to five-fold) were incubated with 100 TCID50 of SARS-
CoV for 1 h, then the mixtures were added to a Vero E6 cell
culture grown to confluence in 96-well microtiter plates. After
48 h, the cells were fixed with 10% formaldehyde and stained
with crystal violet to visualize the cytopathic effects of the virus
(Storch, 2001). Neutralization antibody titers were expressed as
the minimal dilution of sera capable of inhibiting viral
cytopathic effects.
Analysis of the SARS-CoV-specific T-cell response
CLN, ALN and spleens were obtained from mice 1 week
after their third vaccination. Following preparation of a single
cell suspension, T cells were purified using a Pan T cell isolation
kit and a magnetic cell sort system (MACS: Miltenyi Biotec,
Bergisch Gladbach, Germany). To prepare APC, normal BALB/
c mouse splenocytes were depleted of Thy-1+ T cells by MACS
and irradiated at 2000 cGy. Purified T cells (1 × 106) were
cultured with APC (5 × 106) in the presence or absence of UV-
irradiated, purified SARS-CoV virion at 10 μg/ml. Four days
after cultivation, cytokine concentrations within culture super-
natant were measured by flow cytometry using a mouse Th1/
Th2 cytokine cytometric bead array kit (Becton Dickinson, San
Jose, CA).
Generation of a stable S-transfectant
A20.2J murine B cells were transfected with either pEF-S-
bst or pEF-BOS-bst by electroporation at 960 μF and 310 V
using a GenePulser (BioRad Laboratories, Hercules, CA). After
selection using blasticidine S (Invitrogen), followed by limiting
dilution cloning, S6.2 and BOS-5 clones were obtained. To
detect S protein expression in S6.2 cells, the cells were stained
with biotinylated anti-S monoclonal antibody (Ohnishi et al.,
2005) or control antibody, followed by the incubation with
APC-streptavidin (e-Bioscience Inc., San Diego, CA), after
which they were analyzed by FACScalibur (BD Bioscience)
using the Cell Quest II program. Propidium Iodide was used to
exclude dead cells. The data were re-analyzed and depicted
using Flowjo software (Tree Star Inc., San Carlos, CA).
ELISPOT assay
Spleen T cells of mice immunized with rDIsSARS-N or
rDIsSARS- E/M/N/S were separated using a MACS system(Miltenyi Biotec, Auburn, CA). To enrich CD4+ T cells in the T
cell fraction, CD8+ T cells were partially removed using anti-
CD8 mAb-coated magnetic beads (Miltenyi Biotec). This
procedure reduced the number of CD8+ T cells to less than
one third. Overlapping 20-mer peptides covering the whole N
sequences of SARS-CoV were obtained from Sigma-Aldrich
Japan. S peptides S44 (S331–350), S45 (S381–400), S46
(S431–450), and S47 (S481–500) corresponding to the ACE2
binding region of the S protein were selectively produced based
on a web-site program by SYFPEITHI (http://syfpeithi.de/).
A20.2J murine B cells irradiated at 2000 cGy were used as
APCs with peptides corresponding to either S or N proteins. In
some experiments, A20.2J cells stably transfected with pEF-S
or the empty vector pEF-BOS were used.
ELISPOT assays were performed according to the methods
outlined by DIACLONE research (Besancon, France). In brief,
96-well flat-bottom plates (Maxisoap Nunc plates, Nunc,
Rochester, NY) were coated with anti-IFN-γ capture antibody
for one h at 37 °C. The plates were then washed with PBS
containing 0.05% Tween 20 (PBST), and blocked with PBS
containing 2% bovine serum albumin overnight at 4 °C. Freshly
isolated splenic T cells (5 × 105) and APCs (1 × 104) were added
to the plates in the presence or absence of 5 μM of N or S
peptides and incubated for 16 h at 37 °C in 5% CO2 on the anti-
IFN-γ-coated plates, followed by a lysis with ice-cold de-
ionized water. After the plates were washed, biotinylated
detection antibody was added, then the plates were further
incubated for 1 h at 37 °C. The plates were washed three times
with PBST, then 50 μl/well of Streptavidin-alkaline phospha-
tase-conjugated anti-biotin immunoglobulin G solution was
added, followed by incubation for 1 h at 37 °C. After washing
with PBST, substrate mix (50 μl/well) was added, and the plates
were allowed to develop over 4 h at 37 °C. The wells were
imaged and the number of spot-forming cells SFC counted
using a KS ELISPOT compact system (Carl Zeiss, Jena,
Germany).
Histopathology and immunohistochemistry
Lung tissue from the mice was fixed in 10% buffered
formalin and embedded in paraffin. Paraffin block sections were
stained with hematoxylin and eosin (H&E). SARS-CoV
antigens were immunohistochemically detected using a la-
beled-streptoavidin–biotin complex staining system (DakoCy-
tomation Co. Japan, Kyoto, Japan). Rabbit polyclonal
antibodies raised against UV-inactivated, purified SARS-CoV
were used as a primary antibody. A catalyzed signal
amplification method (Dako) was also used to detect SARS-
CoV antigens with enhanced sensitivity. Lung sections from
mice vaccinated with rDIsSARS-E/M/N/S and infected with
SARS Co-V were stained with anti-CD3 antibody. (Santa Cruz
Biotechnology)
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